US 11,911,474 B2
Delivery and formulation of engineered nucleic acids
Antonin De Fougerolles, Waterloo (BE); and Sayda M. Elbashir, Cambridge, MA (US)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Filed by ModernaTX, Inc., Cambridge, MA (US)
Filed on Jan. 5, 2021, as Appl. No. 17/141,753.
Application 15/379,284 is a division of application No. 14/337,513, filed on Jul. 22, 2014, granted, now 9,533,047, issued on Jan. 3, 2017.
Application 17/141,753 is a continuation of application No. 15/927,730, filed on Mar. 21, 2018, granted, now 10,898,574.
Application 15/927,730 is a continuation of application No. 15/379,284, filed on Dec. 14, 2016, granted, now 9,950,068, issued on Apr. 24, 2018.
Application 14/337,513 is a continuation of application No. 13/897,362, filed on May 18, 2013, abandoned.
Application 13/897,362 is a continuation of application No. 13/437,034, filed on Apr. 2, 2012, granted, now 8,710,200, issued on Apr. 29, 2014.
Claims priority of provisional application 61/470,451, filed on Mar. 31, 2011.
Prior Publication US 2021/0386857 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/18 (2017.01); A61K 31/7088 (2006.01); A61K 31/7115 (2006.01); A61K 38/19 (2006.01); A61K 38/48 (2006.01); A61K 47/22 (2006.01); A61K 47/28 (2006.01); C07K 14/535 (2006.01); C12N 15/67 (2006.01); C12N 15/87 (2006.01); C12N 9/64 (2006.01); A61K 48/00 (2006.01)
CPC A61K 47/18 (2013.01) [A61K 31/7088 (2013.01); A61K 31/7115 (2013.01); A61K 38/193 (2013.01); A61K 38/4846 (2013.01); A61K 47/22 (2013.01); A61K 47/28 (2013.01); C07K 14/535 (2013.01); C12N 9/644 (2013.01); C12N 15/67 (2013.01); C12N 15/87 (2013.01); A61K 48/00 (2013.01); C12N 2310/335 (2013.01)] 18 Claims
 
1. A method of producing a polypeptide of interest in a cell in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a modified messenger RNA (mmRNA) such that the mmRNA is introduced into the cell, wherein the mmRNA comprises a translatable region encoding the polypeptide of interest and comprises the modified nucleoside 1-methyl-pseudouridine, wherein the pharmaceutical composition comprises an effective amount of the mmRNA providing for increased polypeptide production and substantially reduced innate immune response in the cell, as compared to a composition comprising a corresponding unmodified mRNA, and wherein 100% of uridines in the mmRNA are replaced with 1-methyl-pseudouridine.